Shardul Amarchand Mangaldas advised Eris Lifesciences Limited in relation to acquisition of India business of Strides Shasun Limited, including acquisition of 100 percent stake in Strides Healthcare Private Limited.
As a part of the transaction, Eris Lifesciences Limited would acquire the domestic branded generics business of Strides Shasun Limited through a business transfer of the Undertaking from Strides Shasun Limited, and acquisition of 100 percent shares of Strides Healthcare Private Limited in which certain brands of the Undertaking are housed.
The transaction team was led by Amit Khansaheb and Roshan Thomas, Partners; and included Prateek Lala, Senior Associate; Hardik Bhatia, Senior Associate; Alekhya Donepudi, Associate; Christopher Rao, Associate and Rimjhim Khandelwal, Associate.
The parties involved in the transaction were Eris Lifesciences Limited; Strides Shasun Limited; and Strides Healthcare Private Limited.
Other advisors to the transaction were Ernst & Young (investment advisor for Eris Lifesciences Limited); MAPE Advisory Group (acted as investment advisor) and Tatva Legal (acted as legal advisor for Strides Shasun Limited).
The value of the deal is USD 75,000,000 (appox.)
The deal was signed on November 18, 2017 and is expected to close by November 30, 2017 (subject to completion of customary conditions precedent).
Disclaimer: No Business Standard Journalist was involved in creation of this content
